Truist Reiterates Buy on Legend Biotech with $70 Price Target
ArchivedSingle Source|2 articles|1 sources|1 blocks
Detected: Updated: Analyzed:
Reported Facts
Observable data points shared across all narratives
- •Truist set the price target for Legend Biotech at $70 as of March 10, 2026.
- •The Buy rating is based on Legend Biotech's production capacity and growth prospects.
- •Legend Biotech operates in the biotechnology industry, focusing on cell therapy products.
What Could Happen If...
- ▸Legend Biotech successfully expands its production capacity the company could increase revenue and meet higher demand, potentially driving its stock price above the $70 target, benefiting investors.
Market Exposure
StocksLegend Biotech stockUpward Pressure
Truist's Buy rating and $70 price target based on production capacity may encourage investor buying interest, supporting the stock price.
This is not investment advice. Market exposure is based on conditional event analysis.
Key Actors
Instruments
Organizations
Source Coverage
FINANCE
2 articles
More coverage on this story
- More on Legend Biotech stock
- More on Legend Biotech
- More on Truist Financial Corporation
Signals
Single-block coverage
Related Events
▸Truist Reaffirms Buy Rating on Silgan Stock Amid Acquisition ReportArchived▸Harmony Biosciences shares fall after Deutsche Bank and Truist downgradeArchived▸Truist Maintains Buy on AbCellera Ahead of Key 2H26 DataArchived▸Truist maintains Buy rating on Universal Technical Institute at $40Archived▸Beta Technologies upgraded at Jefferies on near-term growth catalysts